Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Maintains $80 Price Target
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Maintains $80 Price Target
Canaccord Genuity維持對rhythm pharmaceuticals的買入評級,目標價維持在80美元。
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $80 price target.
Canaccord Genuity分析師Whitney Ijem維持對rhythm pharmaceuticals(納斯達克:RYTM)的買入評級,目標價爲80美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。